Inhibitors Of B-Cell Receptor Molecules Affect Surface CD20 and Impair Antitumor Activity Of Anti-CD20 Monoclonal Antibodies
Bojarczuk K, Winiarska M, Bobrowicz M et al.
Key Points:
In this study authors investigated role of BCR signaling pathways in regulation of CD20 levels in B-cell-derived tumor cells and antitumor activity of anti-CD20 mAbs.
Authors showed: blocking BCR with specific inhibitors or selective shRNA-mediated silencing of SYK or BTK results in down-regulation of CD20.
Implications:
Blocking BCR down-regulates CD20.
Combinations of BCR inhibitors and anti-CD20 mAbs potentially clinically useful in optimized schemes.
View the original abstract on the ASH website.
